Table 2.
Patient characteristics for all steroid‐refractory DSC‐treated patients and controls
| Characteristics | SR group 1, n = 13 | SR group 2, n = 11 | SR MSC, n = 15 | SR controls, n = 32 |
|---|---|---|---|---|
| Sex (M/F) | 6/7 | 7/4 | 11/4 | 18/14 |
| Age at GVHD, years, median (range) | 54.8 (16.4–64.4) | 42.4 (1.6–53.9) | 57 (34–65) | 40.65 (3.7–67.7) |
| Diagnosis (malignant/nonmalignant) | 11/2 | 8/3 | 15/0 | 32/0 |
| Disease status (high risk/low risk) | 8/5 | 6/5 | 6/7 | 17/12 |
| Conditioning (MAC/RIC) | 7/6 | 3/8 | 8/7 | 20/12 |
| ATG (yes/no) | 6/7 | 7/4 | 9/6 | 20/12 |
| GVHD prophylaxis | ||||
| CsA/MTX | 10 | 6 | 14 | 25 |
| CsA/MMF | 0 | 0 | 1 | 7 |
| TAC/SIR | 2 | 3 | 0 | 0 |
| CsA/MTX/Cy | 1 | 2 | 0 | 0 |
| Donor SIB/MUD/CB/haplo | 6/7/0/0 | 4/6/0/1 | 9/5/1/0 | 11/19/2/0 |
| Graft source (PBSCs/BM/CB) | 11/2/0 | 8/3/0/1 | 1/13/1 | 25/5/2 |
| GVHD grade at time of intervention (2/3) | 2/11 | 4/7 | 0/15 | 9/23 |
| GVHD localization (gut and other/only liver) | 13/0 | 11/0 | 15/0 | 27/5 |
| CMV (double‐neg./any pos.) | 2/11 | 4/7 | 1/14 | 2/30 |
| GVHD after DLI (yes/no) | 0/13 | 1/10 | 5/10 | 5/27 |
| HSCT/DLI steroids, days (range) | 33 (10–375) | 27 (5–200) | 28 (11–94) | 25 (8–171) |
| Steroids DSCs, days (range) | 18 (7–37) | 7 (3–23) | 23 (3–90) | N/A |
| Number of infusions (range) | 1 (1–3) | 3 (2–6) | 1 (1–3) | N/A |
| Cell dose (range) | 2.0 (0.9–2.8) | 1.2 (1.0–2.9) | 1.5(0.7–2.0) | N/A |
| Cell passage (range) | 2 (2–3) | 4 (2–4) | 3 (2–3) | N/A |
| Viability, % (range) | 90 (70–97) | 94 (69–100) | >95 | N/A |
Abbreviations: ATG, antithymocyte globulin; BM, bone marrow; CB, cord blood; CMV, cytomegalovirus; CsA, cyclosporine A; Cy, cyclophosphamide; DLI, donor lymphocyte infusion; DSCs, decidua stromal cells; F, female; GVHD, graft‐versus‐host disease; HSCT, allogeneic hematopoietic stem cell transplantation; M, male; MAC, myeloablative conditioning; MTX, methotrexate; MUD, matched unrelated donor; N/A, not applicable; neg., negative; PBSCs, peripheral blood stem cells; pos., positive; RIC, reduced‐intensity conditioning; SIB, sibling donor; SIR, sirolimus; SR, steroid refractory; TAC, tacrolimus.